Low molecular weight heparin and cancer survival: clinical trials and experimental mechanisms

Randomized Phase III Trial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer: FRAGMATIC Trial

(2016) Fergus Macbeth et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of MYC in regulation of tumor cell metabolism

(2015) Therese Wahlström et al.   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

Efficacy of Prophylactic Low–Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial

(2015) Uwe Pelzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Integrins

(2014) Cui-Cui Sun et al.   ANTI-CANCER DRUGS

Preliminary safety evaluation of a taurocholate-conjugated low-molecular-weight heparin derivative (LHT7): a potent angiogenesis inhibitor

(2014) Farzana Alam et al.   JOURNAL OF APPLIED TOXICOLOGY

The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta-analysis of randomized trials

(2014) D. Sanford et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

The Role of Heparanase and Sulfatases in the Modification of Heparan Sulfate Proteoglycans within the Tumor Microenvironment and Opportunities for Novel Cancer Therapeutics

(2014) Edward Hammond et al.   Frontiers in Oncology

The efficacy and safety of low-molecular-weight heparin use for cancer treatment: A meta-analysis

(2013) D.H. Che et al.   European Journal of Internal Medicine

Identification of pro- and anti-proliferative oligosaccharides of heparins

(2013) Qi Ying Lean et al.   Integrative Biology

Suppression of endoplasmic reticulum stress-induced invasion and migration of breast cancer cells through the downregulation of heparanase

(2013) YANG LI et al.   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

(2013) Gary H. Lyman et al.   JOURNAL OF CLINICAL ONCOLOGY

EMT transcription factors: implication in osteosarcoma

(2013) Guoqiong Yang et al.   MEDICAL ONCOLOGY

Cyr61 is a target for heparin in reducing MV3 melanoma cell adhesion and migration via the integrin VLA-4

(2013) Norbert Schütze et al.   THROMBOSIS AND HAEMOSTASIS

Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: Results from the ABEL study

(2013) R. Lecumberri et al.   THROMBOSIS RESEARCH

Heparins modulate the IFN-γ-induced production of chemokines in human breast cancer cells

(2012) Herbert Fluhr et al.   BREAST CANCER RESEARCH AND TREATMENT

The mechanisms of nadroparin-mediated inhibition of proliferation of two human lung cancer cell lines

(2012) Y. Carmazzi et al.   CELL PROLIFERATION

Low-Molecular-Weight Heparin Versus Placebo for the Prevention of Venous Thromboembolism in Metastatic Breast Cancer or Stage III/IV Lung Cancer

(2012) Sylvia K. Haas et al.   CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS

Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer

(2012) Giancarlo Agnelli et al.   NEW ENGLAND JOURNAL OF MEDICINE

Low Molecular Weight Heparin Ablates Lung Cancer Cisplatin-Resistance by Inducing Proteasome-Mediated ABCG2 Protein Degradation

(2012) Qi Niu et al.   PLoS One

Concentration- and time-dependent effects of enoxaparin on human adenocarcinomic epithelial cell line A549 proliferation in vitro

(2011) Walid Abu Arab et al.   CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY

Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer

(2011) A. Maraveyas et al.   EUROPEAN JOURNAL OF CANCER

Randomized Trial of the Effect of the Low Molecular Weight Heparin Nadroparin on Survival in Patients With Cancer

(2011) Frederiek F. van Doormaal et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study

(2011) Sandro Barni et al.   Journal of Translational Medicine

The multivalent activity of the tissue factor–thrombin pathway in thrombotic and non-thrombotic disorders as a target for therapeutic intervention

(2010) Ioannis Mitroulis et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting

(2010) Chrisostomi Gialeli et al.   FEBS Journal

Modulating the interaction of CXCR4 and CXCL12 by low-molecular-weight heparin inhibits hepatic metastasis of colon cancer

(2010) Lixin Ma et al.   INVESTIGATIONAL NEW DRUGS

PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma

(2010) J. R. PERRY et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Heparin-Binding Epidermal Growth Factor-Like Growth Factor Downregulates Expression of Activator Protein-1 Transcription Factor after Intestinal Ischemia-Reperfusion Injury

(2010) Chih-Cheng Luo et al.   Neonatology

Effect of Fraxiparine, a type of low molecular weight heparin, on the invasion and metastasis of lung adenocarcinoma A549 cells

(2010) CHUAN-JIANG YU et al.   Oncology Letters

Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study

(2009) Giancarlo Agnelli et al.   LANCET ONCOLOGY

Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy)

(2008) Hanno Riess et al.   BMC CANCER

Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin

(2007) Marina Marchetti et al.   THROMBOSIS RESEARCH